Abbott Laboratories (ABT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and ...

Abbott had a visible slowdown in top line and earnings margin starting in 2022 and continued in Q1's data. It is likely to have more persistent weakness in the bottom line in '23 and '24 to show up.

On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Organic sales growth for the underlying ...

Abbott Laboratories reported impressive Q3 sales of $10.1B, driven by organic sales growth of 13.8%. The company's diversified portfolio showed growth across all major business segments, including ...

Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter, Abbott ...

Stereotaxis Inc (NYSE:STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE:ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' Robotic ...

Abbott's suite of electrophysiology products includes an ecosystem which combines the 3D mapping system, EnSite X, and a large portfolio of catheters and tools that operate on EnSite X. “The reason ...

Revenues from the company's medical devices segment grew 12% in the quarter, fueled by double-digit gains in diabetes care, heart failure, electrophysiology, and rhythm management, with continuous ...